Can Sanofi Catch Up With Amgen Now That Praluent Has CV Risk-Reduction Claim?
Executive Summary
ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.
You may also be interested in...
Regeneron/Sanofi, Amgen PCSK9 Rivalry Continues, But Not In US Courts
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
Genomics Data Should Get More Attention In FDA Drug Review And Labeling, Regeneron Says
Regeneron advocates industry-FDA collaboration to establish regulatory standards for novel applications of genomic data, such as determining whether long-term outcomes studies are needed, and inclusion of the data in product labeling.
Last Two Of Three Big Inclisiran Studies Boosts The Medicines Co.
Filings for the twice-yearly anti-PCSK9 injection under a partnership with Alnylam are on track, including a fourth quarter submission in the US. Detailed ORION-9 and ORION-10 data will be presented at AHA in November.